Buscar Company Acquires 70% Stake in Armorgenix to Enter Pharmaceutical Market
核心洞察
Buscar Company (搜索) (OTC: CGLD) acquired a 70% stake in Armorgenix Company (搜索) through a strategic stock swap, marking its expansion into the pharmaceutical sector with focus on antiviral and detoxification solutions.
The acquisition includes Armorgenix's clinically evaluated DetoxShield (搜索) product and positions Buscar to capitalize on the U.S. antiviral market valued at $22.2 billion in 2024.
Armorgenix plans to establish a Texas-based manufacturing facility and Wyoming-based IP management entity within 24-36 months to enhance North American market penetration.
Buscar Company (搜索) (OTC: CGLD), a Beverly Hills-based diversified holding company, announced the acquisition of a 70% stake in Armorgenix Company (搜索) through a strategic stock swap, marking a significant expansion into the pharmaceutical sector. The transaction positions Buscar to capitalize on the growing U.S. antiviral and detoxification markets while complementing its existing operations in natural resources and sustainable technologies.
Strategic Acquisition Details
Under the agreement terms, Buscar acquired 70% of Armorgenix's equity through a stock swap valued based on a mutually agreed-upon exchange ratio of Buscar shares. This acquisition follows Buscar's strategic 50% stake acquisition in Terramer Inc. (搜索) in April 2025, further diversifying its portfolio into innovative, high-growth sectors.
Armorgenix, based in Mequon, Wisconsin, will operate as a key subsidiary under Buscar's umbrella, with ambitious expansion plans including a Texas-based manufacturing facility and a Wyoming-based corporation to manage intellectual property, research, and a new brand tailored for North American markets. These initiatives are expected to be operational within 24-36 months, supported by Armorgenix-led fundraising efforts to localize production and enhance market penetration.
Market Opportunity and Financial Projections
The acquisition positions Buscar to capitalize on significant opportunities in the U.S. pharmaceutical market, particularly in the antiviral and detoxification segments. The global antiviral drugs market was valued at $60.6 billion in 2024 and is projected to grow to $62 billion in 2025, reaching $85.4 billion by 2034 at a compound annual growth rate (CAGR) of 3.6%.
The U.S. antiviral market, valued at $22.2 billion in 2024, represents a key driver of this growth, fueled by rising cases of viral infections (搜索) such as HIV/AIDS (搜索), hepatitis (搜索), and influenza (搜索), alongside increasing demand for effective treatments. The HIV/AIDS segment dominates the market, expected to reach $41.2 billion by 2034, driven by the long-term necessity of antiretroviral therapy and streamlined regulatory approvals.
The broader U.S. pharmaceutical market, valued at $799.67 billion in 2024, is projected to grow to $854.83 billion in 2025 and reach $1,447.20 billion by 2032, exhibiting a CAGR of 7.8%. This growth is driven by a rising prevalence of chronic diseases (搜索), an aging population, and robust research and development environments.
Product Portfolio and Clinical Assets
Armorgenix, led by President Boris Nayflish, specializes in the distribution and planned production of advanced pharmaceutical products, including DetoxShield (搜索), a clinically evaluated detoxification solution. The company's DetoxShield and antiviral product pipeline align with market trends, particularly as consumer awareness of preventive healthcare and self-medication grows.
The U.S. Department of Health and Human Services reports that approximately 133 million Americans live with at least one chronic disease, increasing demand for innovative treatments. Armorgenix's planned manufacturing and IP management facilities will enhance its ability to meet this demand, positioning Buscar to capture a share of the growing antiviral and over-the-counter markets.
Strategic Synergies and Leadership Vision
The acquisition strengthens Buscar's diversified portfolio, bridging its expertise in natural resources through Eon Discovery Inc. (搜索) and sustainable materials via Terramer Inc. (搜索) with cutting-edge pharmaceutical solutions. Eon Discovery continues to manage gold mining operations in California's Plumas National Forest, including the Treasure Canyon Lode Mine, providing a stable asset foundation.
"Adding Armorgenix to our family of companies is a pivotal milestone for Buscar," said Alexander Dekhtyar, CEO of Buscar Company (搜索). "This acquisition not only diversifies our portfolio with innovative pharmaceutical solutions but also reinforces our commitment to tackling global challenges, from environmental sustainability to advanced healthcare. We are excited to collaborate with Armorgenix's team to bring life-enhancing products to North American markets and deliver exceptional value to our shareholders."
Market Position and Competitive Advantages
The company's focus on branded drugs, which held a 71.9% market share in 2024 due to their proven efficacy and safety, further strengthens its competitive edge. The over-the-counter drugs market, relevant to Armorgenix's potential expansion into accessible health solutions, is estimated at $42.8 billion in 2024, projected to reach $53 billion by 2029 at a CAGR of 4.4%, driven by consumer shifts toward self-medication and cost savings over prescription drugs.
Nayflish will continue to lead the Armorgenix subsidiary, working closely with Buscar's executive team to execute a strategic roadmap that includes expanding production capabilities and accelerating market entry. The acquisition enhances Buscar's revenue potential by diversifying into the high-growth pharmaceutical sector, complementing the stable cash flows from Eon Discovery's mining operations and the scalability of Terramer's bioplastics.